Aarti Drugs Balance Sheet Health
Financial Health criteria checks 5/6
Aarti Drugs has a total shareholder equity of ₹12.8B and total debt of ₹5.9B, which brings its debt-to-equity ratio to 46%. Its total assets and total liabilities are ₹24.3B and ₹11.5B respectively. Aarti Drugs's EBIT is ₹2.4B making its interest coverage ratio 7.4. It has cash and short-term investments of ₹295.6M.
Key information
46.0%
Debt to equity ratio
₹5.88b
Debt
Interest coverage ratio | 7.4x |
Cash | ₹295.60m |
Equity | ₹12.78b |
Total liabilities | ₹11.52b |
Total assets | ₹24.30b |
Recent financial health updates
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Recent updates
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Sep 20Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 01Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00
Jan 30Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think
May 17These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet
Aug 28Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching
Aug 19Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
May 17Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock
Apr 04Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?
Feb 17Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio
Feb 04What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?
Jan 22Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth
Jan 07If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late
Dec 23Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 23How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?
Nov 08Financial Position Analysis
Short Term Liabilities: AARTIDRUGS's short term assets (₹12.6B) exceed its short term liabilities (₹7.8B).
Long Term Liabilities: AARTIDRUGS's short term assets (₹12.6B) exceed its long term liabilities (₹3.7B).
Debt to Equity History and Analysis
Debt Level: AARTIDRUGS's net debt to equity ratio (43.7%) is considered high.
Reducing Debt: AARTIDRUGS's debt to equity ratio has reduced from 77% to 46% over the past 5 years.
Debt Coverage: AARTIDRUGS's debt is well covered by operating cash flow (52.4%).
Interest Coverage: AARTIDRUGS's interest payments on its debt are well covered by EBIT (7.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 03:27 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aarti Drugs Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Rashmi Sancheti Shetty | CGS International |
Rashmi Sancheti Shetty | Dolat Capital Market Pvt. Ltd. |
Kameswari V. S. Chavali | FirstCall Research |